news Lysosomes key to coronavirus shedding, finds study 29 October 2020 | By Hannah Balfour (Drug Target Review) Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
news Mini lung organoids reveal early SARS-CoV-2 infection process 23 October 2020 | By Victoria Rees (Drug Target Review) Using lung organoids, researchers have shown that 48 hours after SARS-CoV-2 infection, the innate immune response began.
article Treating cytokine storms in COVID-19 patients 23 October 2020 | By Dr Fiona McCann (CannBioRx Life Sciences), Dr H Michael Shepard (Enosi Life Sciences), Sir Marc Feldmann (Enosi Life Sciences) Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
news SARS-CoV-2 also uses neuropilin-1 to infect human cells 21 October 2020 | By Hannah Balfour (Drug Target Review) Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.
news CBD could treat inflammation caused by COVID-19, study shows 20 October 2020 | By Victoria Rees (Drug Target Review) Researchers have found that CBD reduces inflammation in the lungs of COVID-19 mouse models by increasing levels of the apelin peptide.
news SARS-CoV-2 papain-like protease could be a novel drug target 19 October 2020 | By Hannah Balfour (Drug Target Review) Scientists suggest targeting the SARS-CoV-2 papain-like protease (PLpro) with inhibitors could prevent the spread of infection.
news Targeting host proteins could lead to pan-coronavirus antivirals 16 October 2020 | By Hannah Balfour (Drug Target Review) Researchers suggest that targeting host proteins with drugs, rather than directly targeting enzymes or proteins on SARS-CoV-2 and related coronaviruses, could improve outcomes.
news Over 200 molecules and genes linked to COVID-19 severity 14 October 2020 | By Victoria Rees (Drug Target Review) A team has identified 219 molecules and genes that influence the severity of COVID-19 in patients, providing information that could aid the development of therapeutics.
news High doses of favipiravir combat SARS-CoV-2 in hamsters 12 October 2020 | By Victoria Rees (Drug Target Review) A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
news Researchers suggest blocking factor D protein could combat SARS-CoV-2 9 October 2020 | By Victoria Rees (Drug Target Review) A team has said that inhibiting the factor D protein could prevent SARS-CoV-2 from turning the immune system against healthy cells.
news SARS-CoV-2 mechanism of infection revealed using cryo-electron microscopy 8 October 2020 | By Victoria Rees (Drug Target Review) Researchers have found that the surface of SARS-CoV-2 can take on at least 10 different structural states when in contact with ACE2.
news Build-up in the lungs could be targeted by future severe COVID-19 treatments 7 October 2020 | By Hannah Balfour (Drug Target Review) Breaking down or slowing the production of a hyaluronan jelly which builds up in the lungs of some severe COVID-19 patients could reduce respiratory distress and prevent death.
news Scientists propose treating SARS-CoV-2 with sofosbuvir and remdesivir 7 October 2020 | By Victoria Rees (Drug Target Review) Researchers have posited that SARS-CoV-2 could be combatted by sofosbuvir, in combination with other antivirals such as remdesivir.
news SARS antiviral nitric oxide could be used to treat SARS-CoV-2 5 October 2020 | By Victoria Rees (Drug Target Review) The nitric oxide treatment used during the 2003 SARS epidemic could be used as an antiviral against SARS-CoV-2, researchers say.
news Team identifies T-cell epitopes to inform COVID-19 vaccine development 2 October 2020 | By Victoria Rees (Drug Target Review) Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.
